How To Evaluate Your Dispensary's Value

This story is not a valuation, an appraisal, or tax or legal advice. Dollar ranges are illustrations computed from public deals.

How do you evaluate your dispensary? It's complicated, but it isn't guesswork. A non-operating Pennsylvania permit went for $20 million while a rural Nevada store sold for $500,000. Even one closed deal can produce more than one per-store number. Disclosed or pending 2025–2026 deal multiples are one data point, not the answer, and deal prices have swung widely over time. Those differences don't mean any one price is wrong. They show which things move the number, and several of them are within your control.

Here are the things that impact valuation.

No single factor settles the price, and they often pull in different directions. The rest of this story walks through each one, using the deals and the experts.

Vireo Growth closed its all-stock purchase of FLUENT Corp. on Nov. 9, 2026, adding 33 Florida dispensaries and about 117,000 square feet of cultivation and production, plus FLUENT's Buffalo, New York, operations. (Vireo, Nov. 9, 2026; Greenway Magazine, Nov. 9, 2026)

Any owner who hears "33 stores" will be tempted to divide. The deal shows why that's hard. Depending on how you count, it produces more than one per-store figure, and none of them is a template for a single shop doing about $1 million a year.

Two "per-store" numbers. Neither is your store. Close equity divided by 33 stores: about $1.26 million. An illustrative enterprise value divided by 33: about $2.46 million. Cannabis Professional calculations. Close-date debt and cash are not verified, and both figures still include cultivation.

Headline prices are rarely cash at closing, and per-store figures below are Cannabis Professional calculations from company disclosures.

Apply those disclosed revenue multiples, about 0.2x at the low end (Grown Rogue) to about 1.2x at the high end (Union Chill), to a store with about $1 million in sales. The result is a very rough band of $200,000 to $1.2 million. That's a Cannabis Professional estimate, not an appraisal.

A seller who wants a real number needs normalized EBITDA, or seller's discretionary earnings (SDE) for an owner-operator, plus local license supply, lease quality, and tax posture. And the biggest variable is the state.

Before any multiple, the first question is whether the license can be sold at all.

That distinction decides which liabilities come with the store. Horn said: "In Pennsylvania, for example, you can only buy the equity of an entity that holds a permit, and so when you buy the equity you're buying liabilities of the entity. Where in Maryland you can buy just the assets because the license is an asset, and when you do an asset deal you're not, as a matter of law, buying the liabilities."

Calvin Shannon, CPA, CVA, principal and consulting practice leader at BGM Advisory, states the valuation rule that goes with it. "A lot of times deal structure is dictated by state regulations, but as a general rule an asset deal would result in a higher value than an equity deal," Shannon said.

In some states, control can't change hands yet. On New York, Alovisetti said: "There is no process right now to transfer control."

Scarcity matters too.

The deals agree: $20 million for a Pennsylvania permit, $500,000 for a rural Nevada store.

Scarcity sets the ceiling. Federal tax sets how much cash a buyer actually keeps, and that now depends on license type. As of Nov. 12, 2026, according to primary federal sources:

280E as of Nov. 12, 2026: Medical-licensed marijuana has been Schedule III since April 28, 2026 (91 FR 22714). IRS guidance has been promised but not issued. Adult-use is still Schedule I, and 280E still applies.

The valuation effect follows the tax line.

"To the extent the dispensary is trafficking a Sch I controlled substance (at this point medical dispensaries with DEA registration would not be) then yes IRC 280E does reduce cash flow and accordingly will reduce value. Additionally, in theory by the virtue of a DEA registration for a medical dispensary, there would be less risk and that might increase earnings multiple slightly," Shannon said.

Neither source put a number on the gap. Neither will we.

Then comes the form of payment, because the headline isn't the check. TerrAscend paid partly in notes and options. Vireo paid largely in stock that later fell. Strategic buyers can still pay up.

"Another contributing factor is the motivations of a buyer. If a buyer is motivated for strategic reasons to make a specific acquisition is a specific area, then they might be compelled to spend more on the deal," Shannon said.

Horn said: "If you're a small MSO and you're looking to expand your footprint in another state, I suspect you're going to get pushed on the multiple because of that desire."

Those buyers are the exception in a soft market. Horn said: "The M&A space, with some exceptions, has been relatively quiet. What you're seeing is larger companies buying up smaller companies at a discount, quite frankly, because companies are hard pressed to make money. It's been soft for a couple of years."

Retail-only assets can still draw interest. Charles Alovisetti of Vicente LLP told MJBizDaily in March that for a Colorado buyer, "By just doing retail, that's going to counter fixed costs."

"It's a distressed market now. So most transactions... much lower valuations," Charles Alovisetti, Partner at Vicente LLP, told Cannabis Professional by phone on Nov. 13, 2026.

The 2021 deal record shows how far prices have fallen. Verano paid about $134 million for three Pittsburgh-area Healing Center stores, about $44.7 million a store (Verano filing). FLUENT's Pennsylvania operations, including three stores, brought $11.6 million in cash at the end of 2025, about $3.9 million a store (FLUENT FY 2025). Trulieve's all-stock purchase of Harvest priced at about 9.1x Harvest's 2020 revenue (Trulieve, May 10, 2021; Harvest FY 2020). Today's best disclosed store deal, Union Chill, came in at up to about 1.18x. (Cannabis Professional calculations from company disclosures. The 2021 prices include stock valued at announcement, and Harvest was a whole multistate operator, not a store.)

How sellers get paid changed too. "During the years where it was frothy, you saw a lot of stock deals or all stock deals at very high valuations... and now you're seeing a lot of seller notes," Alovisetti said. Cash at closing is a "small percentage" of the price, "maybe 5 to 10 percent," Alovisetti said, "sometimes above that."

For a deal that isn't distressed, he gave a benchmark. "I would say 3.5x EBITDA is a pretty typical multiple," Alovisetti said. Distressed deals are harder to price, he said, because "a lot of those transactions are occurring out of receivership." Public multistate operators averaged over 15x EBITDA in 2021, according to Viridian Capital Advisors, and traded at a median of about 5.5x in early 2025 (Benzinga, Dec. 5, 2022; Benzinga, Feb. 14, 2025).

A note shifts the risk to the seller. "When there's a significant seller note component of the transaction, the seller essentially becomes a lender," Alovisetti said. He advised sellers to check the buyer's credit and the collateral behind the note, including whether a parent company guarantees it.

He described a recent single-store sale he didn't name: more cash at closing than usual, but a significant seller note. It came in at "definitely a lower valuation than the sellers were hoping for," he said, but the owners "wanted to exit the market."

Florida licenses show the same slide. Alovisetti estimated that "there were deals that were happening at 40 million and now it's closer to one, one to 1.5 for license." Public deals confirm the drop, though not his exact figures. Planet 13 agreed to pay $55 million in cash for a bare Florida license in 2021 (Planet 13, Sept. 1, 2021) and sold the subsidiary holding it for $9 million in 2024 (Planet 13 8-K, May 6, 2024). In September, MJBizDaily reported that asking prices for a Florida license were about $4 million. Cannabis Professional found no closed sale at $1 million to $1.5 million.

So what can an owner control? Horn's list is short.

And a signed letter of intent isn't a close. Horn said: "I've had deals crater for any number of reasons: regulatory problems, issues on valuation. If you have a due diligence condition in a deal document and then, when you're conducting additional due diligence, the valuation seems out of whack, they may try to re-trade the deal, and if the seller is not willing to re-trade, those deals crater. It's only a handful where that's happened. Most people are pretty serious when they're in the deal space to work it out."

Alovisetti named two problems that most often cut a price or kill a deal: tax exposure from aggressive past positions, especially when the state requires an equity deal, and an overly demanding landlord.

Tax exposure doesn't have to sink a sale, he said: "People can still do deals with significant tax exposure if there's someone creditworthy who's willing to stand behind the indemnity, because that'll de-risk it significantly for the buyer."

His advice: "Think about the regulatory and structural issues before you start talking to potential buyers... You don't want it to come out during the diligence process."

Not legal, tax, or valuation advice. Use it to set the agenda with your CPA, your attorney, and your state cannabis office.

Cannabis is an industry full of instability: federal tax rules in flux, license rules that change by state, a soft deal market, and buyers who pay in stock that can fall. An owner can't fix any of that. What an owner can do is run an organization that stays steady inside it. The first four steps below bring that stability, and they are the kind of thing a buyer's diligence is likely to probe.

Each one tells a buyer the business will still work the day after the deal closes.

What to expect: state cannabis offices review change-of-ownership or change-of-control filings and must accept a buyer before the license moves. For medical licensees, DEA registration now sits alongside the state license, and a DEA registration is automatically suspended if the state license is suspended, revoked, or expires (91 FR 22714).

What to ask, early and in writing where the agency allows:

Treat a delayed or denied transfer as a value risk, not paperwork. A buyer is paying for a license the regulator has to accept.